Avectas' Solupore® Transfected Cells Isolated Using Sony's CGX10 Yield Highly Cytotoxic CAR-T Cells

This webinar explains how CAR-T cells transfected using Solupore® technology from Avectas and sorted using the CGX10 Cell Isolation System from Sony Biotechnology outperform unsorted cells in single-cell, image-based targeted killing assays.

Isolating and engineering CAR-T cells to enhance their efficacy is an important step in advancing cell therapies. We demonstrate that when used together, the Solupore transfected cells sorted using the CGX10 system yield highly cytotoxic CAR-T cells. This workflow enriches triple-positive CD45RA+, CD62L+, CCR7+ T stem cell memory cells (TSCM) with high purity and viability, which consistently demonstrate superior functionality in single-cell killing assays compared to unsorted cells. The CGX10 system can be effectively integrated both upstream and downstream from the Solupore-based workflow, supporting a streamlined and scalable process for generating potent CAR-T cell therapies.

The CGX10 is a fully closed cell isolation system for GMP-compliant cell production and sorting applications. The innovative system design provides seamless scalability from process development to clinical-scale manufacturing. Avectas’ Solupore technology enhances patient access to autologous T-cell therapies by delivering payloads via a physicochemical mechanism that reversibly permeabilizes the cell membrane, producing healthier engineered cells with a younger memory phenotype.

Who Should Attend?
This webinar will benefit scientists and clinicians working in the cell therapy space (CAR-T, Treg, NK, stem cell) who are interested in non-viral technology for cell engineering (CAR engineering, or CRISPR-Cas9 editing) and need to develop workflows requiring multiparametric selection. The webinar is ideal for specialists, scientists, and engineers in cell and gene therapy manufacturing at the research, process development, or manufacturing stage who are working on applications such as CAR-Treg or Treg, CAR-T, TIL-based, CAR-NK, immune cell, and stem cell therapy.